The FSHD Society is set to improve clinical trial design for facioscapulohumeral muscular dystrophy (FSHD) by deploying Artificial Intelligence (AI) technology.

It has announced the launch of a partnership with the FSHD Clinical Trial Research Network (CTRN) and BullFrogAI for analysing the natural history dataset obtained from FSHD patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The debilitating, genetic disease FSHD causes life-long, progressive muscle weakness.

Under the partnership, BullFrogAI will analyse a large and multidimensional FSHD clinical dataset by leveraging the bfLEAP AI platform.

BullFrogAI’s bfLEAP analytics engine is derived from technology that was developed at the Johns Hopkins University Applied Physics Laboratory (APL) and helps to evaluate complex, multi-factorial data sets.

See Also:

The FSHD CTRN will collect the dataset in the Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD (ReSolve; NCT03458832) study funded by NIH.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A total of 220 patients from eight US and three European CTRN sites took part in the trial, where multiple motor outcome instruments were used for monitoring disease progression over a period of 24 months.

They included an FSHD Functional Composite, Reachable Workspace, the Motor Function Measure Domain 1, and electrical impedance myography.

FSHD Society chief science officer Jamshid Arjomand said: “We hope these studies will help with clinical trial design and patient stratification to accelerate clinical trials for our community.”

The AI analysis helps to evaluate the outcome measures, or combination of measures that are sensitive to changes associated with disease progression.

FSHD CTRN co-director Jeffrey Statland said: “This collaboration can set the stage for more efficient clinical trial design, and can serve as a model for collaborations with AI companies to evaluate large clinical trial preparedness data sets.”